Model: MCF-7 End Point Biomarker
Treatmenta Concentration 2-OHE1: 16α-OHE1b E3: 16α-OHE1b AI Coloniesc
E2 20 nm 0.4 ± 0.1d 0.1 ± 0.1h 36.0 ± 1.5k
E2+LBB 0.05% 5.2 ± 1.3e 2.3 ± 0.3i 2.5 ± 1.0l
E2+LBf 1.0% 0.1 ± 0.09 2.6 ± 0.3j 4.8 ± 1.2m
E2+Co 0.1% 6.8 ± 1.7f 0.4 ± 0.1 4.0 ± 1.2n
E2+Eg 1.0% 1.9 ± 0.5g 0.6 ± 0.2 4.9 ± 1.5o
Table 2: Modulation of End Point Biomarkers in Model for Luminal A Molecular Subtype of Breast Cancer. aE2 at 20 nM and herbal extracts at their respective maximum cytostatic concentrations. bConcentrations of individual E2 metabolites determined by stable isotope dilution and GCMS analysis after a 48 hr treatment. Mean±SD, N=3 per treatment group. cAnchorage independent (AI) colonies counts at day 21 post-seeding of 1,000 cells per well of six-well plates. Mean±SD, N=18 per treatment group. d<e, d<f, d<g Data analyzed by 1-way ANOVA and Dunnett’s multiple comparison test (α<0.05). h<I, h<jData analyzed by 1-way ANOVA and Dunnett’s multiple comparison test (α<0.05). k>l, k>m, k>n, k>o Data analyzed by 1-way ANOVA and Dunnett’s multiple comparison test (α < 0.05).